Previous 10 | Next 10 |
Multidrug resistance is a growing opportunity for investors interested in biotech. The modern world has been experiencing a dramatic decrease in the effectiveness of antimicrobial agents on bacterial pathogens. This is an emerging health problem according to the U.S. Center for Disease Control...
Recorded June 30, 2021. Noble Capital Markets Senior Research Analyst Robert LeBoyer sits down Lineage Cell Therapeutics CEO Brian Culley for this exclusive interview. Topics covered include: Allogeneic approach to cell therapy – an off-the-shelf solution Scalability and control advanta...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen ®...
In the U.S. (2015), about 1.02 million people were blind, and roughly 3.22 million people had impaired vision2. According to data from the CDC’s Disability and Health Data System (2019), the nationwide prevalence of ‘vision disability’ was 5%3. The CDC predicts that the po...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has been added to both the broad-market Russell 3000 ® Index as well as the ...
Biotech Penny Stocks Remain A Focus Heading Into Q3 2021 Penny stocks are well known for their high risk and high reward potential. There aren’t many places where you can buy into an early-stage company, see shares rise 100% or more, and take profit all within a single day or wee...
Lineage Cell Therapeutics (LCTX) perks up 3.7% premarket after providing an update on the clinical advancement of OPC1, its investigational allogeneic oligodendrocyte progenitor cell transplant therapy for the treatment of spinal cord injury ((SCI)).Following FDA feedback,...
RMAT Interaction with FDA Held to Propose Clinical Testing of a Novel Delivery Device for OPC1 Safety Study Eligibility is Expected to Include Patients with Chronic Injury Late-Stage Clinical Study Continues to be Planned for 2022 Lineage Cell Therapeut...
Lineage Cell Therapeutics (LCTX) has granted an exclusive option to privately-held Amasa Therapeutics, to acquire an exclusive, royalty-bearing license to use Lineage’s HyStem technology for the development and commercialization of therapies for local treatment of solid tumors.Under th...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced it granted an exclusive option to Amasa Therapeutics, Inc. (Amasa), a privately-held biopharmaceut...
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...